Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_assertion description "[Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_assertion evidence source_evidence_literature NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_assertion SIO_000772 15746945 NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_assertion wasDerivedFrom befree-2016 NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_assertion wasGeneratedBy ECO_0000203 NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.
- befree-2016 importedOn "2016-02-19" NP483852.RAkkHvzsrzQZ4_puYf97-F4K0EnzPrVn4EWD9ZA401bHg130_provenance.